Trubion Pharmaceuticals Inc. Announces Upcoming Presentation at the 2007 American Society of Hematology Annual Meeting

SEATTLE, Dec. 6 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. today announced that certain data regarding the company's TRU-016 (CD37 SMIP(TM)) program will be presented at the 49th annual meeting of the American Society of Hematology (ASH). The meeting will be held Dec. 8-11, 2007, at the Georgia World Congress Center in Atlanta.


[801] Role of CD37 SMIP, a Novel Engineered Small Modular Immunopharmaceutical, in the Treatment of CLL


Rosa Lapalombella, Xiaobin B. Zhao, Peter R. Baum, Jeffrey A. Ledbetter, Natarajan Muthusamy, John C. Byrd, Division of Hematology and Oncology, Department of Internal Medicine; Division of Pharmaceutics, The Ohio State University, Columbus, Ohio, USA; Trubion Pharmaceuticals, Seattle, Wash., USA

About Trubion

Trubion is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. The company's product candidates are novel proteins known as single-chain polypeptides and are designed using its SMIP custom drug assembly technology. In December 2005, the company entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of certain therapeutics, including TRU-015. In addition, Trubion's TRU-016 program targets CD37, an antigen present on B cells, for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma. The company filed an IND for TRU-016 in the fourth quarter of 2007. Trubion currently retains all development and commercialization rights for the TRU-016 program. For additional information visit


CONTACT: Jim DeNike, Senior Director, Corporate Communications of Trubion
Pharmaceuticals Inc., +1-206-838-0500,; or Jenny Moede,
Senior Vice President of Waggener Edstrom Worldwide Healthcare,
+1-503-443-7000,, for Trubion Pharmaceuticals

Web site:

Back to news